

## **Remarks**

### **Claims**

Claims 1, 3-6, 8-15, 19-26, 30, 35-37, 39, 40, 42, 43 and 51-58 are allowed. Claims 2, 7, 16-18, 27-28, 34, 38, 41 and 44-49 previously were cancelled. Claims 29, 31-33 and 50 were cancelled an the Examiner's amendment. New claims 59-66 are added.

New claim 59 recites a pharmaceutical composition of a subset of previously claimed ALA ester salts. Support for new claims 59-66 can be found in the specification at least at page 8, lines 11-16 and lines 35-37, page 10, lines 16-31, pages 29-32, Examples 1-4 and 7-8 and at page 40, Example 28. These new claims add no new matter. Applicants reserve the right to pursue any unclaimed subject matter in a continuing or divisional application.

### **Information Disclosure Statement**

An information disclosure statement ("IDS") accompanies this amendment. The IDS cites certain references that the Canadian Examiner cited as prior art against claims pending in the corresponding Canadian application CA 2561050 (the remaining references that the Canadian Examiner cited as prior art against the pending claims were previously made of record in this case).

### **Conclusion**

It is believed that the subject claims are in condition for allowance, which action is earnestly solicited. If, in the opinion of the Examiner, a telephone conference would expedite prosecution of the subject application, the Examiner is invited to call the undersigned attorney.

The Office is authorized to charge any fees that may be necessary for consideration of this paper to Kenyon & Kenyon Deposit Account No. 11-0600.

Respectfully submitted,

Dated: July 20, 2010

By: /Lawrence H. Frank/

Lawrence H. Frank  
Reg. No. 51,700

KENYON & KENYON LLP  
One Broadway  
New York, NY 10004  
(212) 425-7200